A precise understanding of how the enzyme topoisomerase II cuts DNA could lead to better anti-cancer therapies.
News: Genome Maintenance Research Program
A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.
Vanderbilt investigators have discovered a new DNA repair pathway that guards against genomic mutations. Their findings were published recently in the journal Cell.
Changes in enzymes involved in lysophospholipid signaling can activate a pathway implicated in development of cancer, a recent study suggests.
Vanderbilt researchers have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.
A recent study shows that a component of the DNA primase enzyme acts as a reversible on/off switch for DNA binding and represents a fundamentally new method of communication between DNA-processing enzymes.
Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.
A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
Vanderbilt researchers have identified a previously undetected type of histone modification that may have implications for cancer and other conditions.
A recent study showing that protein called RADX helps regulate the process of DNA repair may help us better understand why some cancers are more or less resistant to certain therapies